サンプル依頼リスト カート
  • English
  • Korean
表紙：インフルエンザ治療薬の世界市場-2023年～2030年
市場調査レポート
商品コード
1373370

インフルエンザ治療薬の世界市場-2023年～2030年

Global Influenza Therapeutics Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
インフルエンザ治療薬の世界市場-2023年～2030年
出版日: 2023年10月18日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

インフルエンザは、悪寒、発熱などの症状を伴う、インフルエンザウイルスによるインフルエンザ様疾患です。ほとんどの人は、すでに感染している患者の咳やくしゃみから空気中に浮遊する小さな飛沫を吸い込むことでインフルエンザに感染します。疾病管理予防センターは、死に至る深刻なリスクを予防するために、毎年インフルエンザの予防接種を受けることを推奨しています。

インフルエンザの流行は毎年発生しており、インフルエンザのような症状がある人の多くは、抗ウイルス薬や抗菌薬などの市販薬を使用しています。世界保健機関（WHO）によると、世界全体のインフルエンザ罹患率は毎年、小児人口の20％から30％、成人人口の約10％です。インフルエンザによる死亡者数は年間約29万～65万人です。

市場力学：市場促進要因と市場抑制要因

臨床試験の増加

ワクチンの臨床試験は、その安全性、免疫原性、有効性プロファイルを試験しながら進行中です。これらのワクチンは、有効性と安全性を高め、有害な影響を減らすために開発されています。例えば、clinical.govによると、マヒドン大学とGovernment Pharmaceutical Organizationは、季節性3価不活化スプリットビリオンインフルエンザワクチンであるTri Fluvacの免疫原性と安全性を評価する第3相臨床試験を実施しています。開始日は2020年8月3日。終了予定日は2023年12月31日です。

米国国立アレルギー感染症研究所（NIAID）は、健康成人を対象としたモザイク六価インフルエンザワクチンVRC-FLUMOS0116-00-VP（FluMos-v2）の安全性と忍容性を評価する第1相臨床試験を実施しています。開始日は2023年8月9日。完了予定日は2024年12月16日。

南京善信医薬有限公司は、中国の成人合併症のないインフルエンザ患者を対象に、ZX-7101Aを比較する第2相および第3相試験を実施しています。ZX-7101Aの安全性と有効性も評価します。試験開始日は2022年9月17日。終了予定日は2024年6月30日。

抗ウイルス薬の副作用

インフルエンザ治療薬の副作用は軽度で、吐き気や嘔吐など治療可能なものです。気管支痙攣や下痢を起こす抗ウイルス薬はほとんどありません。バロキサビルのような他の薬剤は、妊婦や授乳中の女性が服用すると重篤な合併症を引き起こすため、経口オセルタミビルは妊婦に推奨されています。根本的なリスクのため、ザナミビルは7歳以上の早期インフルエンザ治療薬として承認されています。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • 臨床試験の増加
      • YY社
    • 抑制要因
      • 抗ウイルス薬の副作用
      • YY
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • DMI意見

第6章 COVID-19分析

第7章 疾患タイプ別

  • A型インフルエンザ
  • B型インフルエンザ
  • C型インフルエンザ
  • D型インフルエンザ

第8章 治療薬別

  • 治療薬
    • 抗ウイルス剤
    • バロキサビル
    • オセルタミビル
    • ペラミビル
    • その他
    • 抗菌薬
    • リマンタジン
    • アマンタジン
    • その他
  • ワクチン
    • 不活化インフルエンザ・ワクチン（IIV）
    • 生ワクチン（LAIV）
    • その他

第9章 投与経路別

  • 経口
  • 吸入
  • 注射剤

第10章 エンドユーザー別

  • 病院および診療所
  • 専門センター
  • その他

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ

第12章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第13章 企業プロファイル

  • Merck KGaA
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展
  • Santa Cruz Biotechnology, Inc.
  • Biosynth
  • Teva Pharmaceuticals USA, Inc.
  • Biorbyt Ltd.
  • Thermo Fisher Scientific Inc.
  • Steris Healthcare PVT Ltd.
  • Genentech, Inc.
  • Lupin Pharmaceuticals, Inc.
  • BioCryst Pharmaceuticals, Inc.

第14章 付録

目次
Product Code: PH1525

Overview

Influenza is a flu-like illness caused by the influenza virus with symptoms such as chills, fever, etc. Most people contract the flu by breathing in tiny airborne droplets from the coughs or sneezes of already infected patients. The Centers for Disease Control and Prevention recommends people get flu shots annually to prevent serious risks that lead to death.

Outbreaks of influenza occur every year, and many people with flu-like symptoms use over-the-counter medication such as anti-viral drugs, anti-microbial drugs, etc. According to the World Health Organization (WHO), the annual global influenza attack rate ranges from 20% to 30% of the child population and around 10% of the adult population. The number of deaths due to influenza is approximately 290,000-650,000 annually.

Market Dynamics: Drivers & Restraints

Increasing clinical trials

Clinical trials are ongoing for vaccines, testing their safety, immunogenicity, and efficacy profiles. These vaccines are developed to increase efficacy and safety and decrease the harmful effects. For instance, according to clinical.gov, Mahidol University and the Government Pharmaceutical Organization conduct phase 3 clinical trials to evaluate the immunogenicity and safety of Tri Fluvac, a seasonal trivalent inactivated split virion influenza vaccine. The start date is August 3, 2020. The estimated completion date is December 31, 2023.

The National Institute of Allergy and Infectious Diseases (NIAID) is conducting a phase 1 clinical trial to assess the safety and tolerability of a Mosaic Hexavalent Influenza Vaccine VRC-FLUMOS0116-00-VP (FluMos-v2) in Healthy Adults. The start date is August 9, 2023. The estimated completion date is December 16, 2024.

Nanjing Zenshine Pharmaceuticals conducts phase 2 and 3 trials to compare ZX-7101A in Chinese adult patients with uncomplicated influenza. The safety and efficacy of ZX-7101A is also assessed. The study start date is September 17, 2022. The estimated completion date is June 30, 2024.

Side effects of anti viral drugs

Influenza drug side effects are mild and treatable, such as nausea and vomiting. Few anti-viral drugs cause bronchospasm as well as diarrhea. Oral oseltamivir is recommended for pregnant women as other medications like Baloxavir have severe complications when taken by pregnant women or breastfeeding women, as there is no safety data available for this drug. Due to the underlying risks, Zanamivir is approved for early flu treatment in people seven years and older.

Segment Analysis

The global influenza therapeutics market is segmented based on disease type, therapeutics, route of administration end user and region.

The vaccines segment accounted for approximately 52.3% of the market share

Vaccines are the most effective treatment for influenza compared to drugs, as vaccines give long-term protection to the patient. mRNA vaccines work more precisely and quickly as they destroy the primary target and cure the disease. Vaccine manufacturers like Pfizer and Moderna are working on the launch of mRNA vaccines for influenza.

In September 2022, Pfizer Inc. initiated clinical trial phase 3 to evaluate the efficacy, tolerability, and immunogenicity of quadrivalent modified RNA (modRNA) influenza vaccine.

In February 2023, Moderna initiated a phase 3 clinical trial to assess the safety and efficacy of mRNA-1010, a seasonal influenza vaccine candidate.

Geographical Analysis

North America accounted for approximately 41.2% of the market share in 2022

North America is expected to hold the largest share in the market owing to the presence of giant vaccine manufacturers such as Pfizer, moderna, etc., and the increasing prevalence of the disease in the US, Canada, etc. Several people from flu belong to the North American region.

Influenza is a contagious disease which affects more that affects nearly 8% of the U.S. population annually. According to the World Health Organization (WHO), Seasonal influenza leads to an estimated 650,000 deaths worldwide yearly. More than 90% of influenza deaths occur in adults at least 65.

According to the Government of Canada's annual report on seasonal influenza, During the 2021-2022 influenza season, 16,126 laboratory-confirmed influenza detections were reported out of 751,900 total laboratory tests. Nearly 71% of seniors (65 and older) are affected by influenza yearly.

COVID-19 Impact Analysis:

COVID-19 has significantly impacted the influenza therapeutics market as there is a shift in the focus on developing vaccines and drugs for the treatment of COVID-19. Lockdowns are implemented worldwide, which halted many processes like supply chain and doctor visits. Diagnosis and treatment of influenza were postponed due to the fear of contracting the infection. As there was an emergency in the COVID-19 vaccine development, the other research activities were stopped by government authorities.

Competitive Landscape

The major global players in the influenza therapeutics market include: Merck KGaA, Santa Cruz Biotechnology, Inc., Biosynth, Teva Pharmaceuticals USA, Inc., Biorbyt Ltd., Thermo Fisher Scientific Inc., Steris, Healthcare PVT Ltd., Genentech, Inc., Lupin Pharmaceuticals, Inc., BioCryst Pharmaceuticals, Inc. among others.

Key Developments

  • In March 2023, eMed launched Urgent Care Telehealth Kit to enable same-day clinical evaluation and prescription medicine for four common illnesses which include COVID-19, influenza, urinary tract infection (UTI), and strep throat.
  • In September 2023, Clover Biopharmaceuticals, Ltd. Launched AdimFlu-S (QIS) in China, the only imported quadrivalent flu vaccine approved for use in individuals aged 3 years and older.

Why Purchase the Report?

  • To visualize the global influenza therapeutics market segmentation based on disease type, therapeutics, route of administration, end-user and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of influenza therapeutics market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global influenza therapeutics market report would provide approximately 69 tables, 67 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Disease Type
  • 3.2. Snippet by Therapeutics
  • 3.3. Snippet by Route of Administration
  • 3.4. Snippet by End user
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Driver
      • 4.1.1.1. Increasing clinical trials
      • 4.1.1.2.
    • 4.1.2. Restraints
      • 4.1.2.1. Side effects of Antiviral drug
      • 4.1.2.2.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Disease Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 7.1.2. Market Attractiveness Index, By Disease Type
  • 7.2. Influenza Type A*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Influenza Type B
  • 7.4. Influenza Type C
  • 7.5. Influenza Type D

8. By Therapeutics

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutics
    • 8.1.2. Market Attractiveness Index, By Therapeutics
  • 8.2. Medication*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
      • 8.2.2.1. Antiviral Agents
      • 8.2.2.1.1.1. Baloxavir
      • 8.2.2.1.1.2. Oseltamivir
      • 8.2.2.1.1.3. Peramivir
      • 8.2.2.1.1.4. Others
      • 8.2.2.2. Anti-Microbial Agents
      • 8.2.2.2.1.1. Rimantadine
      • 8.2.2.2.1.2. Amantadine
      • 8.2.2.2.1.3. Others
  • 8.3. Vaccines
      • 8.3.1.1. Inactivated Influenza Vaccine (IIV)
      • 8.3.1.2. Live Attenuated Influenza Vaccine (LAIV)
      • 8.3.1.3. Others

9. By Route of Administration

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 9.1.2. Market Attractiveness Index, By route of administration
  • 9.2. Oral*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Inhaled
  • 9.4. Injectables

10. By End User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.1.2. Market Attractiveness Index, By End User
  • 10.2. Hospitals and Clinics*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Specialty Centers
  • 10.4. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutics
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutics
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. UK
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutics
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutics
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutics
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Merck KGaA
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Santa Cruz Biotechnology, Inc.
  • 13.3. Biosynth
  • 13.4. Teva Pharmaceuticals USA, Inc.
  • 13.5. Biorbyt Ltd.
  • 13.6. Thermo Fisher Scientific Inc.
  • 13.7. Steris Healthcare PVT Ltd.
  • 13.8. Genentech, Inc.
  • 13.9. Lupin Pharmaceuticals, Inc.
  • 13.10. BioCryst Pharmaceuticals, Inc.

LIST NOT EXHAUSTIVE.

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us